Long-Term Outcome of Soft Tissue Sarcomas Treated With Mesna-Doxorubicin-Ifosfamid-Dacarbazine Regimen (Maid): A Retrospective Study From a Singe Institution

Abstract

Aim:fSoft tissue sarcomas (STSs) account for 1% of cancers in the adult population. The treatment of choice is surgery but chemotherapy and/or radiotherapy are frequently used due to aggressive cancer behavior or incomplete surgery. Doxorubicin-based regimens are the most frequently used chemotherapy combinations but real-life data about the efficacy and safety of these agents in our country is limited. We aimed to present clinicodemographic and prognostic features of STS cases treated with mesna, doxorubicin, ifosfamide, dacarbazine (MAID regimen).Materials and Methods:A total of forty-five STS cases who were diagnosed between 2007-2016 and treated with the MAID regimen as the initial therapy in Cukurova University were analyzed retrospectively. Associations between clinicodemographic parameters with overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and with the logrank test. Univariate-multivariate analyses were used to assess the prognostic values of parameters for OS-PFS.Results:The median age of the patients was 49 and the most common STS subtypes were undifferentiated pleomorphic carcinoma (37.8%) followed by liposarcoma (17.8%) and leiomyosarcoma (13.3%). According to the AJCC TNM stages, 15.6% stage 1-2, 53.3% stage 3, and 31.1% stage 4 disease. The median PFS/OS were 17/39 months, respectively. The 5-year PFS/OS rates were 14%/32.5%, respectively. In univariate analyses, mitosis, necrosis, stage, and surgery were both prognostic for PFS-OS. However, in multivariate analysis, only stage was an independent prognostic factor both for PFS-OS.Conclusion:Stage was the only independent prognostic factor for both PFS-OS in patients with STS who received the MAID chemotherapy as initial therapy.

Keywords

• soft tissue sarcoma
• prognosis
• doxorubicin